Literature DB >> 15599744

Concepts, rationale, and current outcomes of less invasive surgical strategies for early gastric cancer: data from a quarter-century of experience in a single institution.

Shouji Shimoyama1, Yasuyuki Seto, Hidemitsu Yasuda, Ken-ichi Mafune, Michio Kaminishi.   

Abstract

Previously proposed criteria of less invasive surgery for early gastric cancer (EGC) were based mainly on the pathological analyses of the resected specimens; however, preoperative and intraoperative information are also obviously essential for decision making on stage-dependent patient management. Furthermore, most indications and treatment options have not been systematically integrated or evaluated by treatment outcomes. We investigate in this report the rationality of less invasive surgery employed for EGC. Distribution analyses of positive nodes were investigated among 684 patients with primary solitary EGC (379 mucosal and 305 submucosal) who underwent curative resection between 1976 and 2000. Clinicopathological factors highlighted and analyzed included clinical (preoperative and intraoperative) and pathological (postoperative) cancer depth and nodal involvement, gross form, histological type, and maximum cancer diameter, as well as postoperative morbidity and mortality. The scope of lymphadenectomy can be reduced to a modified D1 for clinically mucosal, node-negative, nonpalpable gastric cancer, or for clinically submucosal, node-negative gastric cancer < or = 1.5 cm for intestinal type, or < or = 1.0 cm for diffuse type. Otherwise, a modified D2 lymphadenectomy is sufficient. Local resection can be recommended for clinically mucosal, node-negative gastric cancer without apparent ulceration < or = 4 cm if adjacent lymph nodes are proved cancer negative by a frozen section examination. If the gastric cancer has spread beyond the above criteria, a pylorus-preserving gastrectomy (PPG) can be recommended for tumors located in the middle or lower third of the stomach, provided the distal margin of the cancer is at least 4.5 cm from the pyloric ring. The PPG can be accompanied by a modified D1 or a modified D2 lymphadenectomy according to the respective dissection criteria. Results of these less invasive strategies showed reduced morbidity and mortality, as well as no recurrence or cancer-related deaths. These results suggest that each of our criteria for less invasive surgery for EGC is realistic, well stratified, and satisfactory.

Entities:  

Mesh:

Year:  2005        PMID: 15599744     DOI: 10.1007/s00268-004-7427-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  56 in total

1.  Postoperative functional evaluation of pylorus-preserving gastrectomy for early gastric cancer compared with conventional distal gastrectomy.

Authors:  T Imada; Y Rino; M Takahashi; M Suzuki; J Tanaka; M Shiozawa; K Kabara; S Hatori; H Ito; Y Yamamoto; T Amano
Journal:  Surgery       Date:  1998-02       Impact factor: 3.982

2.  Lymphadenectomy for cure in patients with early gastric cancer and lymph node metastasis.

Authors:  T Okamura; S Tsujitani; D Korenaga; M Haraguchi; H Baba; Y Hiramoto; K Sugimachi
Journal:  Am J Surg       Date:  1988-03       Impact factor: 2.565

3.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

4.  Is D2 lymph node dissection necessary for early gastric cancer?

Authors:  Takaki Yoshikawa; Akira Tsuburaya; Osamu Kobayashi; Motonori Sairenji; Hisahiko Motohashi; Yoshikazu Noguchi
Journal:  Ann Surg Oncol       Date:  2002-05       Impact factor: 5.344

Review 5.  Modern treatment of early gastric cancer: review of the Japanese experience.

Authors:  Yosuke Adachi; Norio Shiraishi; Seigo Kitano
Journal:  Dig Surg       Date:  2002       Impact factor: 2.588

6.  Is lymphadenectomy necessary for early gastric cancer?

Authors:  S N Hochwald; M F Brennan; D S Klimstra; S Kim; M S Karpeh
Journal:  Ann Surg Oncol       Date:  1999 Oct-Nov       Impact factor: 5.344

7.  Benefits of D2 lymph node dissection for patients with gastric cancer and pN0 and pN1 lymph node metastases.

Authors:  J R Siewert; R Kestlmeier; R Busch; K Böttcher; J D Roder; J Müller; C Fellbaum; H Höfler
Journal:  Br J Surg       Date:  1996-08       Impact factor: 6.939

8.  Sentinel node concept in gastric carcinoma.

Authors:  Takashi Ichikura; Daisaku Morita; Takefumi Uchida; Eiji Okura; Takashi Majima; Toshiya Ogawa; Hidetaka Mochizuki
Journal:  World J Surg       Date:  2001-12-17       Impact factor: 3.352

9.  Lymph node metastasis and preoperative diagnosis of depth of invasion in early gastric cancer.

Authors:  Y Seto; S Shimoyama; J Kitayama; K Mafune; M Kaminishi; T Aikou; K Arai; K Ohta; A Nashimoto; I Honda; H Yamagishi; Y Yamamura
Journal:  Gastric Cancer       Date:  2001       Impact factor: 7.370

10.  Clinicopathological features of mucosal carcinoma of the stomach with lymph node metastasis in eleven patients.

Authors:  D Korenaga; M Haraguchi; S Tsujitani; T Okamura; R Tamada; K Sugimachi
Journal:  Br J Surg       Date:  1986-06       Impact factor: 6.939

View more
  10 in total

1.  Segmental gastrectomy with radical lymph node dissection for early gastric cancer.

Authors:  Takeru Matsuda; Kunihiko Kaneda; Manabu Takamatsu; Keishi Aishin; Masahide Awazu; Akiko Okamoto; Katsunori Kawaguchi
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

2.  Prognostic relevance of p53 and bcl-2 immunoreactivity for early invasive pT1/pT2 gastric carcinomas: indicators for limited gastric resections?

Authors:  R Kopp; J Diebold; I Dreier; C Cramer; J Glas; G Baretton; K W Jauch
Journal:  Surg Endosc       Date:  2005-09-21       Impact factor: 4.584

3.  Physiological evaluation of residual stomach motility after local resection in conscious dogs.

Authors:  Keisuke Kubota; Yusuke Tatsutomi; Masaki Kitajima; Ken-ichi Mafune; Keiichiro Ohta; Masashi Yoshida; Tatsushi Suwa; Junko Kuroda; Naoki Hiki; Yasuyuki Seto; Michio Kaminishi
Journal:  Surg Today       Date:  2011-05-01       Impact factor: 2.549

4.  Effects of mosapride citrate on patients after vagal nerve preserving distal gastrectomy reconstructed by interposition of a jejunal J pouch with a jejunal conduit for early gastric cancer.

Authors:  Ryouichi Tomita; Taro Ikeda; Shigeru Fujisaki; Tugumichi Koshinaga; Katsuhisa Tanjoh
Journal:  World J Surg       Date:  2006-02       Impact factor: 3.352

5.  Survival of early gastric cancer in a specialized European center. Which lymphadenectomy is necessary?

Authors:  Maurizio Degiuli; Fabio Calvo
Journal:  World J Surg       Date:  2006-12       Impact factor: 3.352

Review 6.  Current status of function-preserving surgery for gastric cancer.

Authors:  Takuro Saito; Yukinori Kurokawa; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

7.  Discussion of modifying stage IV gastric cancer based on Borrmann classification.

Authors:  Bin Yang; Guoqiang Wu; Xiaochen Wang; Xuefeng Zhang
Journal:  Tumour Biol       Date:  2013-02-13

8.  Endoscopic submucosal dissection for gastric cancer.

Authors:  Mitsuhiro Fujishiro
Journal:  Curr Treat Options Gastroenterol       Date:  2008-04

9.  Higher Risk of Lymph Node Metastasis in Young Patients with Early Gastric Cancer.

Authors:  Zu-Kai Wang; Jian-Xian Lin; Ping Li; Jian-Wei Xie; Jia-Bin Wang; Jun Lu; Qi-Yue Chen; Long-Long Cao; Mi Lin; Ru-Hong Tu; Chang-Ming Huang; Chao-Hui Zheng
Journal:  J Cancer       Date:  2019-07-23       Impact factor: 4.207

10.  Prognostic significance of intraoperative macroscopic serosal invasion finding when it shows a discrepancy in pathologic result gastric cancer.

Authors:  Sang Yull Kang; Ho Sung Park; Chan-Young Kim
Journal:  Ann Surg Treat Res       Date:  2016-05-02       Impact factor: 1.859

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.